Just as New Zealand’s fragile economic recovery shows flickers of improvement – with economists predicting its annual growth could surpass that of its larger neighbour Australia – it is facing a new threat: the war in the Middle East. New Zealand is particularly exposed to the energy shocks produced by the conflict – and to economic crises generally – with the small, isolated nation highly depende...
Just as New Zealand’s fragile economic recovery shows flickers of improvement – with economists predicting its annual growth could surpass that of its larger neighbour Australia – it is facing a new threat: the war in the Middle East. New Zealand is particularly exposed to the energy shocks produced by the conflict – and to economic crises generally – with the small, isolated nation highly dependent on global trade and tourism. It is susceptible to disruptions in supply chains and shipping. “We would far prefer this wasn’t happening to the New Zealand economy, and it’s not good for the New Zealand economy,” finance minister Nicola Willis said this week. The economy and cost of living will be the central issues in elections, set to take place in November, and while confidence had been building – and New Zealand is showing signs its economy is finally drawing a line under its worst stretch in almost two decades – the war creates new uncertainty. “We’ve been through an economic trough that’s been just as deep and prolonged … as that which followed the global financial crisis,” said Benje Patterson, an independent economist. New Zealand’s economy has been battered by recession and stagnation that arrived in the wake of the Covid-19 pandemic. The country struggled to find its feet as inflation piled pressure on businesses and drove households to rein in spending. “It’s been a tough couple of years – like, really tough. We’ve had significant reduction in the economy, job losses, business closures, all that kind of stuff,” says Shamubeel Eaqub, an economist. “But [there are] signs that things are kind of bottoming out and beginning to improve.” On Thursday, New Zealand will release its latest economic figures, assessing growth before the impact of the conflict. Gross domestic product (GDP) data is expected to show New Zealand’s economy grew 1.6% over the course of 2025, according to a Westpac forecast. Growth in New Zealand is then set to accelerate to 2.8% this year, the ...
酒店房租稅｜去年第三、第四季合共稅收4.2億元 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】政府去年重新徵收酒店房租稅，去年第三及第四季合共稅收4.2億元。 財經事務及庫務局局長許正宇書面回覆立法會議員查詢，說...
酒店房租稅｜去年第三、第四季合共稅收4.2億元 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】政府去年重新徵收酒店房租稅，去年第三及第四季合共稅收4.2億元。 財經事務及庫務局局長許正宇書面回覆立法會議員查詢，說過去8個月，每月平均約300間酒店及130多間賓館須繳付酒店房租稅，涉及約9萬間房間，佔總數約八成四，去年第三季及第四季稅收分別1.8億元及2.4億元。許正宇強調稅額只佔房租3%，而根據旅發局統計，去年平均酒店入住率及過夜旅客人次按年上升2%及6%。重申酒店房租稅提供穩定收入，亦不會影響普羅市民，現時沒計劃調整稅率。
iQoncept/iStock via Getty Images This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers' 13F stock portfolio on a quarterly basis. It is based on Baker Brothers' regulatory 13F Form filed on 02/17/2026. The 13F portfolio value increased from $13.84B to $17.08B. Although there are ~100 positions in the 13F portfolio, the holdings are concentrated am...
iQoncept/iStock via Getty Images This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers' 13F stock portfolio on a quarterly basis. It is based on Baker Brothers' regulatory 13F Form filed on 02/17/2026. The 13F portfolio value increased from $13.84B to $17.08B. Although there are ~100 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. There are 31 positions that are significantly large (more than 0.5% of the portfolio each), and they are the focus of this article. The largest five stakes are Incyte, BeOne Medicines, Madrigal Pharma, Insmed, and ACADIA Pharma. They add up to ~54% of the portfolio. Please visit our Tracking Baker Brothers Portfolio series to get an idea of their investment philosophy and our previous update for the fund's moves during Q3 2025. Baker Brothers, a biotech investment firm, was founded by Julian & Felix Baker in 2000. Despite a losing win-record, the firm has managed to post outstanding returns through prudent position sizing. As a percentage of AUM, allocation to the highest conviction picks can be very high at over 30%. Note 1: Although the position sizes relative to the overall portfolio are very small, Baker Brothers has significant ownership stakes in the following businesses - Cerus Corporation ( CERS ), Entrada Therapeutics ( TRDA ), KALA BIO ( KALA ), Monte Rosa ( GLUE ), Neurogene ( NGNE ), Prelude Therapeutics ( PRLD ), Sagimet Bio ( SGMT ), Sera Prognostics ( SERA ), TScan Therapeutics ( TCRX ), and vTv Therapeutics ( VTVT ). Note 2: Over the years, the firm had a number of home runs as the invested firms got acquired at huge premiums. Recent M&A winners include Pharmacyclics (acquired by AbbVie), Synageva (acquired by Alexion), Salix (acquired by Valeant), Alexion (acquired by AstraZeneca), Global Blood Therapeutics (acquired by Pfizer), ChemoCentryx (acquired by Amgen), Seagen (acquired by Pfizer), and Mirati Therapeutics (acquired by Bristo...
Torsten Asmus/iStock via Getty Images Overview The Fund’s benchmark, the MSCI Emerging Markets Index (net), returned 4.7% in US dollar terms in 4Q25, extending year-to-date leadership versus developed market peers. Macro and industry dynamics supported the gain. Among geographic regions, Latin America and Europe, the Middle East, and Africa (EMEA) outperformed Asia. Although Korea posted index-lea...
Torsten Asmus/iStock via Getty Images Overview The Fund’s benchmark, the MSCI Emerging Markets Index (net), returned 4.7% in US dollar terms in 4Q25, extending year-to-date leadership versus developed market peers. Macro and industry dynamics supported the gain. Among geographic regions, Latin America and Europe, the Middle East, and Africa (EMEA) outperformed Asia. Although Korea posted index-leading returns for the period, China’s weakness weighed on the region. Country drivers were differentiated: Asia’s tech hubs, South Korea and Taiwan, continued to benefit from artificial intelligence ('AI') and semiconductor demand, anchoring emerging market performance. However, China’s markets moderated in recent months after earlier strength, as soft economic data tempered momentum. Indian equities were broadly in line with the index, as positive domestic policies and solid economic growth were offset by external pressures and a weaker rupee. Latin American markets benefited from commodity and policy support. In December, however, after a strong run, performance turned volatile in Brazil. Political concern took hold when jailed ex-President Bolsonaro tapped his son to run in his place instead of the market-friendly Sao Paulo state governor. Chile and Peru returned double digits, benefiting from strong copper prices. In the EMEA region, South African equities led, aided by strong precious metals prices. Banks’ performance was also strong, benefiting several local markets. In contrast, oil prices were weak, which weighed on the Middle East region, with Saudi Arabia the weakest performer during the period. Among sectors, information technology outperformed led by semiconductors, closely followed by more value-oriented sectors like financials and materials. Style wise, value outperformed growth during the period. Within the Fund For 4Q25, Nomura Systematic Emerging Markets Equity Fund Institutional Class shares outperformed the Fund’s benchmark, the MSCI Emerging Markets Index...
Generally, when investors are looking for growth, they turn to industries such as technology. Here, revenue may be rising in the double or even triple digits, leading to explosive stock performance. But in recent years, one specific area of the pharmaceutical market has offered a similar opportunity. And that is in the weight loss drug space. Right now, Eli Lilly (LLY 5.94%) leads this market, wit...
Generally, when investors are looking for growth, they turn to industries such as technology. Here, revenue may be rising in the double or even triple digits, leading to explosive stock performance. But in recent years, one specific area of the pharmaceutical market has offered a similar opportunity. And that is in the weight loss drug space. Right now, Eli Lilly (LLY 5.94%) leads this market, with Novo Nordisk in second position, but many pharma and biotech players are knocking on the door -- and one of the first to enter may be Viking Therapeutics (VKTX 1.36%). The company is studying its candidate in two different forms in phase 2 and phase 3 trials, and so far, the results have been strong. So, right now, if you can only buy one weight loss drug stock, which one should you choose: Lilly or Viking? Let's find out. The case for Eli Lilly Eli Lilly actually wasn't the first to the GLP-1 drug market; Novo Nordisk paved the way, gaining approval for Ozempic for type 2 diabetes in 2017. Doctors prescribed the injectable off-label for weight loss, and that set off the rush by patients into GLP-1 drugs -- and the rush by investors to get into GLP-1 stocks. Lilly entered the market with tirzepatide, commercialized at Mounjaro for type 2 diabetes and Zepbound for weight loss, shortly after Novo, and began gaining market share. The newcomer focused on investing in manufacturing capacity to address demand, and a head-to-head study showed that Lilly's drug resulted in greater weight loss than Novo's. These elements have helped Lilly push ahead in the U.S. market -- it now holds a 60% share. Though Novo was the first to launch a weight loss drug in pill form late last year, Lilly's oral candidate may soon enter the market -- it's under regulatory review right now. Expand NYSE : LLY Eli Lilly Today's Change ( -5.94 %) $ -58.77 Current Price $ 930.35 Key Data Points Market Cap $935B Day's Range $ 925.25 - $ 981.16 52wk Range $ 623.78 - $ 1133.95 Volume 5.6M Avg Vol 3.1M Gross M...
Key Points Eli Lilly is the leader in the U.S. weight loss drug market, with a 60% share. Viking aims to enter this market -- and so far, its clinical trial results have been strong. 10 stocks we like better than Eli Lilly › Generally, when investors are looking for growth, they turn to industries such as technology. Here, revenue may be rising in the double or even triple digits, leading to explo...
Key Points Eli Lilly is the leader in the U.S. weight loss drug market, with a 60% share. Viking aims to enter this market -- and so far, its clinical trial results have been strong. 10 stocks we like better than Eli Lilly › Generally, when investors are looking for growth, they turn to industries such as technology. Here, revenue may be rising in the double or even triple digits, leading to explosive stock performance. But in recent years, one specific area of the pharmaceutical market has offered a similar opportunity. And that is in the weight loss drug space. Right now, Eli Lilly (NYSE: LLY) leads this market, with Novo Nordisk in second position, but many pharma and biotech players are knocking on the door -- and one of the first to enter may be Viking Therapeutics (NASDAQ: VKTX). The company is studying its candidate in two different forms in phase 2 and phase 3 trials, and so far, the results have been strong. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » So, right now, if you can only buy one weight loss drug stock, which one should you choose: Lilly or Viking? Let's find out. The case for Eli Lilly Eli Lilly actually wasn't the first to the GLP-1 drug market; Novo Nordisk paved the way, gaining approval for Ozempic for type 2 diabetes in 2017. Doctors prescribed the injectable off-label for weight loss, and that set off the rush by patients into GLP-1 drugs -- and the rush by investors to get into GLP-1 stocks. Lilly entered the market with tirzepatide, commercialized at Mounjaro for type 2 diabetes and Zepbound for weight loss, shortly after Novo, and began gaining market share. The newcomer focused on investing in manufacturing capacity to address demand, and a head-to-head study showed that Lilly's drug resulted in greater weight loss than Novo's. These elements have helped Lilly pus...
(RTTNews) - Woodside Energy has appointed Elizabeth Westcott as Chief Executive Officer and Managing Director. She has served as Acting CEO since the departure of Meg O'Neill in December 2025. Since joining the company in June 2023, Westcott has led Woodside's Australian operations—including the Scarborough Energy Project and the Bass Strait operator transition—as Executive Vice President and Chie...
(RTTNews) - Woodside Energy has appointed Elizabeth Westcott as Chief Executive Officer and Managing Director. She has served as Acting CEO since the departure of Meg O'Neill in December 2025. Since joining the company in June 2023, Westcott has led Woodside's Australian operations—including the Scarborough Energy Project and the Bass Strait operator transition—as Executive Vice President and Chief Operating Officer Australia. Prior to Woodside, she was Chief Operating Officer at EnergyAustralia, following a 25-year career at ExxonMobil across Australia, the United Kingdom, and Italy. WDS.AX was trading at A$31.64 up A$0.22 or 0.70%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.